A medical device go-to-market strategy is how a cleared device gets paid for, trusted, and used: reimbursement, KOLs, a sales model, and hospital integration. It is not how the device is built, and it is not the 510(k) file.
If you meant how the device is built → medical device development process. If you meant FDA path → FDA medical device approval process. If you meant PMS after launch → medical device post-market surveillance. If you meant hospital / PACS / EMR integration → medical device integration.
If the device is imaging software, PYCAD is the imaging stack (viewer / model), not the regulatory agent / QMS vendor / GTM shop.
Five pillars
| Pillar | What you owe | How you know it worked |
|---|---|---|
| Regulatory and clinical | Clearance or approval, plus evidence a clinician will read | Letter in hand; papers, not just a bench deck |
| Reimbursement and payer | Code, coverage, payment — or a cash path you can defend | A written coverage policy and a real average payment |
| KOL and champions | Named clinicians who will use it and say so | Talks, investigator studies, not a logo slide |
| Sales model | Direct, distributor, or hybrid — matched to complexity | Cycle time, CAC, and whether the device is still on the shelf |
| Hospital integration | EMR / PACS / DICOM in the existing workflow | Days to first live study; physicians still using it at 90 days |
Clearance without a payer story is a warehouse. A payer story without a champion is a brochure. Integration without either is an IT ticket.
Regulatory and reimbursement as one problem
Pick the path before you freeze the design. 510(k), De Novo, or PMA in the U.S.; CE mark under MDR in Europe. That choice sets the clinical package and the calendar. The how-to is FDA medical device approval process. This page only needs the GTM rule: the same data that satisfies FDA should be usable in a payer dossier. Do not run two science programs.
Reimbursement is coding, coverage, and payment. Coding: is there a CPT / HCPCS / DRG that fits, or do you need a new one. Coverage: will the plan pay for that code for your indication. Payment: is the rate enough to cover the device and the time. HEOR is how you answer “does this lower readmissions, minutes in the OR, or complications” with numbers, not adjectives.
A surgical imaging device that lands inside the hospital PACS is a reimbursement argument — less training, fewer minutes per case, fewer lost studies — not a feature list. How the wire actually lands is medical device integration.
Clinical trust, then a sales engine
Trials that only satisfy a reviewer do not move a department chair. Design at least one question a surgeon already argues about. Then find the people who will run that question: a small clinical advisory board, investigator-initiated work you actually fund, a slot at the meeting they already attend. Give them a way to look at studies and mark them without a VPN circus. That is advocacy, not a consulting invoice.
Sales structure follows the device. Direct: expensive, right for a consultative, high-touch implant or capital system. Distributor: fast coverage, weak control, easy to become catalog filler. Hybrid: direct in dense territories, distributors elsewhere. Startups often borrow a network, then hire once the message is stable. Train whoever stands in the room on what the device cannot do. A oversold first case is a lost champion.
Hospital integration is adoption
If the device is imaging, the clinician already has a viewer and a worklist. A second app is a reason to say no. DICOM in, report out, identity from the EMR — that is the bar. The integration how-to is medical device integration. After go-live, post-market data (complaints, real-world performance) is PMS, not a GTM metric dashboard.
FAQ
Can we launch while the 510(k) is in review?
Not in the U.S. You cannot market a device that needs a 510(k) or PMA until the letter is in hand. You can line up KOLs, payer conversations, and integration work. You cannot sell.
What if there is no code?
Then you need a cash or new-tech path, or you wait on a code. “We’ll figure reimbursement out after clearance” is how devices sit in a closet.
Is PYCAD a GTM or reimbursement shop?
No. If the device is imaging software, PYCAD is the imaging stack (viewer / model), not the launch agent. Case studies.